Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | BTK | Q06187 | 14/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294448 | 0.88 | BTK (0.41) | BTKTDO2 | |
| SCHEMBL858696 | 0.88 | BRAF (0.42) | BTK | |
| SCHEMBL13027102 | 0.86 | BTK (0.39) | BTK | |
| SCHEMBL1086259 | 0.86 | NPC1 (0.38) | BTKTDO2 | |
| SCHEMBL414305 | 0.84 | GRM8 (0.40) | BTKTDO2 | |
| SCHEMBL417056 | 0.83 | AAK1 (0.43) | BTK | |
| SCHEMBL1724389 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP2C9 | |
| SCHEMBL13189387 | 0.79 | BTK (0.39) | CYP2C9BTK | |
| SCHEMBL2898883 | 0.77 | CYP3A4 (0.44) | CYP3A4CYP2C9 | |
| SCHEMBL13067186 | 0.76 | CYP2C19 (0.56) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901301-B2 | Pyrrolo[2,3-]pyridine kinase inhibitors | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901301-B2 | Pyrrolo[2,3-]pyridine kinase inhibitors | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286178-A1 | COMPOUNDS AND USES THEREOF | BRAF, RAF1, FER | CYP3A4 3815/4885CYP2C9 2194/4885BTK 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.